#LATEST NEWSFaeth Therapeutics has announced topline clinical data from its Phase II trial of PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib, given with paclitaxel. The drug is being trialled in patients with advanced endometrioid endometrial cancer and a PI3K/AKT/mTOR (PAM) pathway mutation, who had received at… Read More
#LATEST NEWSSRTD Biotech has announced the successful completion of an oversubscribed €31.5 million seed financing round. The financing was led by Mérieux Equity Partners, with NRW.BANK and Boehringer Ingelheim Venture Fund joining the syndicate as co-leads. Lilly Ventures, HTGF, and the Freiburg-based family Office Anobis Asset also participated… Read More
#LATEST NEWSThe first patient has been successfully dosed in OVACT, Epitopea’s first-in-human Phase I/Ib clinical trial evaluating its lead programme, CryptiVax-1001, targeting advanced high-grade serous ovarian cancer (HGSOC). OVACT is designed to evaluate the safety, tolerability, immunogenicity, and early clinical activity of CryptiVax-1001 in HRP+/BRCA-wildtype advanced HGSOC patients. … Read More
#LATEST NEWSLonza has signed a definitive agreement to acquire five CDMO manufacturing sites in the US from Merck (Darmstadt, Germany) at a total enterprise valuation in the low- to mid-triple-digit millions Swiss francs. The acquisition expands Lonza’s US CDMO manufacturing footprint from four to nine sites and complements its global network… Read More
#LATEST NEWSThis new free download can help researchers avoid assay development delays. Download this reference list from Crown Bioscience, which shows what is already validated and ready to run. You will learn: 500+ Human IHC markers for RUO, IVD or CDx Prevalidated 5 to 7-color mIF panels suitable for IO and… Read More
10 November 2026 · Diana Turner
4 November 2026 · Diana Turner
30 October 2026 · Diana Turner
10 November 2026 · Megan Thomas
9 November 2026 · Diana Turner
6 November 2026 · Diana Turner
